Outset Medical (NASDAQ:OM) Issues Quarterly Earnings Results

Outset Medical (NASDAQ:OM - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04), Zacks reports. The business had revenue of $29.47 million for the quarter, compared to the consensus estimate of $28.47 million. Outset Medical had a negative return on equity of 175.64% and a negative net margin of 112.57%. Outset Medical updated its FY 2025 guidance to EPS.

Outset Medical Trading Down 8.8 %

NASDAQ OM traded down $0.08 during trading on Friday, reaching $0.88. 696,815 shares of the stock traded hands, compared to its average volume of 1,430,621. The firm has a market cap of $47.01 million, a price-to-earnings ratio of -0.35 and a beta of 2.01. The stock's 50-day moving average price is $0.95 and its 200 day moving average price is $0.83. The company has a quick ratio of 5.04, a current ratio of 6.49 and a debt-to-equity ratio of 4.12. Outset Medical has a fifty-two week low of $0.44 and a fifty-two week high of $5.22.

Insider Activity at Outset Medical

In other news, CFO Nabeel Ahmed sold 34,288 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $0.80, for a total value of $27,430.40. Following the completion of the transaction, the chief financial officer now owns 258,869 shares in the company, valued at $207,095.20. This represents a 11.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Leslie Trigg sold 65,236 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $0.80, for a total transaction of $52,188.80. Following the completion of the transaction, the chief executive officer now owns 895,580 shares of the company's stock, valued at $716,464. This trade represents a 6.79 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 292,750 shares of company stock worth $244,707. 4.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Separately, Royal Bank of Canada reissued a "sector perform" rating and set a $3.00 price target on shares of Outset Medical in a research note on Tuesday, January 7th.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.